[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tempus AI\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":228},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,76,107,139,162,182,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100586150","multi-site-study-of-the-clinical-impact-of-an-ai-assisted-approach-to-referring-patients-with-interstitial-lung-disease-for-diagnostic-evaluation-of-pulmonary-hypertension-100586150",false,"NCT06911632","Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension","MOMENTOUS Study (iMpact Of an Ecg ai ModEl oN The Diagnosis Of pUlmonary hypertenSion)","MOMENTOUS","Inclusion Criteria:\n\n* 18 years or older at the time of consent\n* A known diagnosis of interstitial lung disease\n* Diffusing capacity for carbon monoxide (DLCO) \\\u003C30% predicted, collected within 3 months prior to consent\n* Willing and able to provide informed consent and undergo all study-specific procedures, including echo and RHC, if required\n\nExclusion Criteria:\n\n* A known diagnosis of pulmonary hypertension (including patients prescribed a therapy specifically for pulmonary arterial hypertension (PAH))\n* A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent\n* LV ejection fraction ≤ 40% on most recent echo or cardiac MRI, if available\n* Unclassifiable Tempus PH ECG risk result after up to 2 ECG acquisitions\n* A contraindication to RHC exists (for example, pregnancy or mechanical right heart valve)\n* Physician decision that if a patient is directed to RHC by the study protocol, the potential risks of RHC outweigh the potential benefits\n* There is a severe concomitant illness limiting life expectancy to less than 6 months (at the discretion of the investigator)\n* There is a medical or social factor that makes the patient a poor candidate for the study and\u002For unlikely to be able to comply with the study protocol or complete study procedures (at the discretion of the investigator)","ALL","18 Years",{"count":20,"type":21},900,"ESTIMATED","INTERVENTIONAL",[24],"NA","MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.",[27,28],"Pulmonary Hypertension","Interstitial Lung Disease (ILD)",[27,30],"Interstitial lung disease (ILD)","RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2025-07-23",{"date":39,"type":21},"2028-07",{"name":41,"class":42},"Tempus AI","INDUSTRY",30,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100604846","a-longitudinal-multi-center-molecular-biomarker-discovery-registry-for-patients-with-hematologic-malignancies-100604846","NCT07154823","A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies","Aquarius","All Cohorts Inclusion Criteria:\n\n1. Willing and able to participate in the research and provide biospecimens\n2. Willing and able to provide informed consent\n\nCohort 001 Inclusion:\n\n1. Have documented diagnosis of AML according to the World Health Organization (WHO) classification\n2. Secondary AML is allowed\n\nCohort 002 Inclusion:\n\n1. Histologically confirmed diagnosis of Follicular Lymphoma (Subgroups A-D)\n2. Submission of baseline sample representative of current disease per laboratory manual (Subgroups A-D)\n3. 002A (Newly Diagnosed Active Observation): On active observation for 6 more or less, or intended for active observation\n4. 002B (Newly Diagnosed, High Risk): Intended for first line treatment\n5. 002B (Newly Diagnosed, High Risk): Meets the criteria for high risk by any of the following: Follicular Lymphoma Inernational Prognostic Index (FLIPI) High Risk, Groupe d'Etude des Lymphomes Follicularies (GELF) High Tumor Burden, Lactate Dehydrogenase (LDH) above the upper limit of normal (ULN)\n6. 002C (Relapsed \u002F Refractory High Risk POD24 FL): Documented progression of disease within 24 months (POD24) of first line follicular lymphoma treatment, prior to second line treatment\n7. 002D (Transformed FL): Pathologically confirmed transformation\n\nAll Cohorts Exclusion Criteria:\n\n1\\. Not willing or able to adhere with the study procedures\n\nCohort 001:\n\n1\\. Have received any prior therapy intended for standard of care (SoC) treatment of AML\n\nCohort 002:\n\n1. 002A: Received prior treatment for follicular lymphoma\n2. 002A: Diagnosed with High Risk follicular lymphoma by any of the following definitions: FLIPI High Risk, GELF High Tumor Burden, LDH above ULN\n3. 002A: Resected patients with NED\n4. 002B: Intended for active observation\n5. 002B: Received prior treatment for follicular lymphoma","0 Years",{"count":53,"type":21},550,"5 Years","OBSERVATIONAL","The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and\u002For bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.",[58,59],"Acute Myeloid Leukaemia (AML)","Follicular Lymphoma ( FL)",[61,62,63,64,65,66],"Hematologic Malignancy","Acute Myeloid Leukemia","AML","Next Generation Sequencing","NGS","Follicular Lymphoma","2026-06-11",{"date":69,"type":35},"2026-06-15",{"date":71,"type":35},"2026-01-27",{"date":73,"type":21},"2035-11",{"name":41,"class":42},6,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":55,"phases":4,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100459048","tempus-small-cell-lung-cancer-observational-study-sculptor-100459048","NCT05257551","Tempus Small Cell Lung Cancer Observational Study (Sculptor)","Tempus SCLC Observational Study: A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays","The following are the inclusion criteria. Participants are eligible to be included in this study only if all the following criteria apply. The participant has\u002Fis:\n\n1. Histologically confirmed small cell lung cancer diagnosis\n2. Diagnosis made with excisional or core needle biopsy specimen (fine needle aspirate may be permitted with approval from the Medical Monitor)\n3. Subjects must submit tumor sample per the laboratory manual, defined as follows: 1L Cohort - Tissue obtained prior to the initiation of 1L therapy; 2L Cohort - Tissue obtained prior to the initiation of 1L therapy and\u002For a standard of care re-biopsy prior to the start of 2L therapy, if performed.\n4. ECOG performance status of 0-2 at time of enrollment\n5. For participants entering prior to first line therapy, planned extensive stage first-line therapy of etoposide plus platinum plus PD-L1 inhibitor (atezolizumab or durvalumab)\n6. For participants entering post completion of standard of care first line prior to second line therapy, completion of an EP+CPI with or without maintenance therapy. Note: Participants who received 1L therapy that is not standard of care i.e., investigational therapy, are not eligible.\n7. Extensive stage disease at time of diagnosis according to NCCN definition: Extensive Stage Small Cell Lung Cancer (SCLC) as either Stage IV disease (any T, any N, with M1a\u002Fb\u002Fc) or T3-4 disease due to multiple lung nodules that are too extensive or have a tumor\u002Fnodal volume that is too large to be encompassed in a tolerable radiation plan (NCCN version 2.2026-September 16, 2025).\n8. Willing and able to provide informed consent\n9. Palliative radiotherapy is permitted as long as there is measurable disease outside of the radiotherapy port with which to assess response to therapy delivered\n\nParticipants will be excluded from the study if any of the following criteria apply. The participant has\u002Fis:\n\n1. Patients with a secondary malignancy must have been both diagnosed \\> 3 years from the lung cancer of interest and have completed all therapy for that malignancy \\> 3 years prior to diagnosis of the lung cancer of interest, with the exception of the following:\n\n   1. Patients with superficial basal cell carcinoma of low-risk histology per NCCN Guidelines (Low-risk histologic subtypes include nodular, superficial, and other non-aggressive growth patterns such as keratotic, infundibulocystic, and fibroepithelioma of Pinkus) and low-risk for recurrence per NCCN Guidelines (location on trunk or extremities, size \\\u003C 2 cm, primary (not recurrent), with well-defined borders) can be included even if they are diagnosed \\\u003C 3 years from the lung cancer of interest.\n   2. Patients with superficial squamous cell carcinoma of low-risk pathology per NCCN Guidelines (verrucous, keratoacanthomatous) and low-risk for recurrence per NCCN Guidelines (located on trunk or extremities; ≤ 2 cm in size; primary lesion (vs. recurrent); well to moderately differentiated; \\\u003C 2 mm thick and no invasion beyond subcutaneous fat; negative for perineural invasion; and negative for lymphatic or vascular involvement) can be included even if they are diagnosed \\\u003C 3 years from the lung cancer of interest.\n2. Mixed small cell and non-small cell histology\n3. Small cell cancers of origin in other organs or suspected metastatic cancer from other sites (i.e., those without a known or suspected lung primary diagnosis)\n4. Large Cell Neuroendocrine cancers\n5. Carcinoids or atypical carcinoid tumors\n6. Transformed small cell lung cancer emerging in the setting of targeted therapy for NSCLC\n7. Treated with an investigational agent of another immunotherapy class (i.e., non PD-1 or PD-L1 inhibitor)\n8. Not willing to have additional blood samples collected",{"count":84,"type":21},200,"3 Years","The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker profiling during standard of care therapy in both first and second line treatment.",[88],"Small Cell Lung Cancer",[90,91,92,93,94,95,88,65,96,97,98,99],"Cancer","Oncology","Observational","Genomic Profiling","Precision medicine","SCLC","Biomarkers","ctDNA","Transcriptomics","Extensive Stage",{"date":69,"type":35},{"date":102,"type":35},"2022-07-13",{"date":104,"type":21},"2029-03",{"name":41,"class":42},11,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":116,"conditions":117,"keywords":123,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},"100609178","evaluating-minimal-residual-disease-mrd-through-longitudinal-circulating-tumor-dna-ctdna-profiling-in-breast-malignancies-100609178","NCT07211178","Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies","GEMINI Breast","Inclusion Criteria:\n\nAll Cohorts:\n\n1. Willing and able to participate in the research and provide biospecimens\n2. Willing and able to provide informed consent\n3. Must be diagnosed with breast cancer\n\nCohort 1: Neoadjuvant Treatment Cohort 1A: Newly Diagnosed, High Risk HR+,HER2-\n\n1. A known or suspected HR+, HER2- breast cancer treated with curative intent (Stage II to III disease)\n2. Patients are considered at high risk of recurrence, defined as 4 or more positive axillary lymph nodes (ALNs), or between 1-3 positive ALNs and either grade 3 disease or tumor size of 5 cm or larger.\n\nCohort 1B: HER2+ 1. A known or suspected HER2+ breast cancer treated with curative intent (Stage II to III disease). Inclusive of HR+ or HR- patients.\n\nCohort 1C: Triple Negative Breast Cancer\n\n1\\. A known or suspected triple negative breast cancer treated with curative intent (Stage I to III disease).\n\nCohort 2: Adjuvant Therapy \u002F Surveillance Cohort 2A: Newly Diagnosed HR+,HER2-\n\n1. A known or suspected HR+, HER2- breast cancer treated with curative intent (Stage II to III disease)\n2. Patients are considered at high risk of recurrence, defined as 4 or more positive axillary lymph nodes (ALNs), or between 1-3 positive ALNs and either grade 3 disease or tumor size of 5 cm or larger.\n3. Have undergone curative intent surgery with no clinical evidence of disease.\n\nCohort 2B: HER2+\n\n1. A known or suspected HER2+ breast cancer treated with curative intent (Stage II to III disease)\n2. Have undergone curative intent surgery with no clinical evidence of disease.\n\nCohort 2C: Triple Negative Breast Cancer\n\n1. A known or suspected triple negative breast cancer treated with curative intent (Stage I to III disease)\n2. Have undergone curative intent surgery with no clinical evidence of disease.\n\nCohort 3: 5-Years Post-Diagnosis Surveillance (NED)\n\n1. A known HR+, HER2- breast cancer treated with curative intent (Stage II to III disease).\n2. No Evidence of Disease (NED) ≥ 5 years from initial diagnosis.\n3. Patients are considered at high risk of recurrence, defined as 4 or more positive axillary lymph nodes (ALNs), or between 1-3 positive ALNs and either grade 3 disease or tumor size of 5 cm or larger.\n\nExclusion Criteria:\n\n1. Not willing or able to adhere with the study procedures\n2. Active secondary malignancy\n3. Diagnosis of a malignancy within 3 years of breast cancer diagnosis Note: Ductal carcinoma in situ (DCIS, ipsilateral or contralateral) within 3 years is not excluded.","99 Years",{"count":20,"type":21},"For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later.\n\nA way to find these cells is by looking for tiny bits of cancer DNA that are shed into the blood. This is called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA. This research aims to see if finding this cancer DNA in the blood can help predict if a patient's cancer will return. It also may help find out if the treatment is working.\n\nUltimately, the results of this research may help doctors better manage breast cancer and develop new and improved tests and treatments.",[118,119,120,121,122],"Breast Cancer","TNBC - Triple-Negative Breast Cancer","HR Positive\u002FHER-2 Negative Breast Cancer","HER2 + Breast Cancer","Early Stage Breast Cancer",[124,125,126,65,97,122,127,128,129],"Minimal Residual Disease","MRD","Next generation sequencing","TNBC - Triple Negative Breast Cancer","HR positive \u002F HER-2 negative breast cancer","HER2+ breast cancer","2026-06-10",{"date":132,"type":35},"2026-06-12",{"date":134,"type":35},"2025-10-27",{"date":136,"type":21},"2033-12",{"name":41,"class":42},14,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":146,"targetDuration":148,"studyType":55,"phases":4,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":43},"100528650","a-longitudinal-multi-omic-biomarker-profiling-study-of-patients-with-head--neck-squamous-cell-carcinoma-hnscc-100528650","NCT06163534","A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)","TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)","Inclusion Criteria:\n\n* ≥18 years of age\n* Willing and able to provide informed consent\n* Histologically- or cytologically-confirmed metastatic or unresectable, recurrent HNSCC unsuitable for local therapies\n* Intended for first line anti-PD1 or PDL1 monotherapy or combination therapy\n* Must submit tumor tissue sample representative of current disease per laboratory manual\n\nExclusion Criteria:\n\n* Non-squamous histologies (eg, nasopharynx or salivary gland)\n* Relapse or recurrence within 6 months of first line chemotherapy and \u002F or chemoradiotherapy\n* Tumors that are PD-L1 negative (CPS \\\u003C1)\n* Clinical evidence of an active second invasive malignancy within \\\u003C2 years of enrollment with the exception of stable prostate cancer on watchful waiting, in situ cervical cancer, in situ breast carcinoma or localized non-melanoma skin cancers\n* Unable to comply with study procedures (i.e., not willing or able to have additional blood samples collected)",{"count":147,"type":21},500,"1 Year","The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.",[151],"Head and Neck Squamous Cell Carcinoma",[91,96,93,153,90,92,154,155,65],"HNSCC","Registry","Precision Medicine",{"date":132,"type":35},{"date":158,"type":35},"2024-08-01",{"date":160,"type":21},"2028-03-01",{"name":41,"class":42},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":114,"enrollmentInfo":168,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},"100531994","tempus-aries-a-biobank-registry-platform-study-in-oncology-100531994","NCT06207032","TEMPUS ARIES: A Biobank Registry Platform Study in Oncology","Inclusion Criteria:\n\n1. ≥18 years of age\n2. Willing to participate in the research\n3. Able to provide informed consent\n4. Must be diagnosed with cancer\n\nExclusion Criteria:\n\n1\\. Not willing or able to have additional blood samples collected",{"count":147,"type":21},"This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.",[90],[97,172,91],"Next-Generation Sequencing","2026-02-20",{"date":175,"type":35},"2026-02-24",{"date":177,"type":35},"2024-06-26",{"date":179,"type":21},"2029-06-01",{"name":41,"class":42},32,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":204},"100457401","gemini-nsclc-nsclc-biomarker-study-100457401","NCT05236114","GEMINI-NSCLC: NSCLC Biomarker Study","TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)","For Cohort 1 Inclusion, the participant has\u002Fis:\n\n* A known or suspected NSCLC treated with curative intent -(surgery with or without perioperative (neoadjuvant or adjuvant) therapy).\n\n  * Suspected NSCLC - Patients with a high index of suspicion for the diagnosis of NSCLC that is resectable may sign informed consent prior to undergoing diagnostic procedure at the discretion of the physician. NCCN Guidelines allow for clinical stage IA cancers to proceed directly to definitive surgery. Per NCCN Guidelines, if a preoperative tissue diagnosis has not been obtained, then an intraoperative diagnosis will be obtained. If a diagnosis of NSCLC is not confirmed and\u002For the tumor is not resectable, then the patient will be a screen failure.\n* Undergone or planning to undergo a surgical resection - (Patients with stages I-IIIB who are resectable - per NCCN guidelines of resectability)\n* Both patients who lack molecular abnormalities and those with identified molecular abnormalities may enroll. Choice of perioperative therapy is to follow SOC therapeutic guidelines for the participant's molecular and PD-L1 profile.\n* 18 years old or older\n* Willing and able to provide informed consent\n* Willing to have additional blood samples collected during routine surveillance visits\n* Must submit tumor sample representative of current disease\n\nFor Cohort 1 Exclusion, the participant has\u002Fis:\n\n* Patients with superior sulcus tumors who are candidates for preoperative concurrent chemoradiation.\n* Stage III locally advanced and unresectable patients who are candidates for chemoradiation followed by immunotherapy.\n* It is expected that all patients on the cohort will be treated with a definitive surgical resection. Thus, clinical stage IIIB and IIIC patients who subsequently demonstrate pathologically confirmed N3 nodal disease or T4 N2 or 3 per any confirmatory procedure listed in NCCN guidelines for which definitive chemoradiotherapy rather than surgery is recommended per NCCN Guidelines are not eligible.\n* Patients who receive primary radiation (in lieu of surgery if they are not surgical candidates).\n\nFor Cohort 2 Inclusion, the participant has\u002Fis:\n\n* Histologically documented Stage IV NSCLC (de novo metastatic or relapse setting) not amenable to curative surgery or radiation therapy. Palliative radiation (for instance for impending bony fracture or to control pain) is allowed at any time during the protocol at the physician's discretion.\n* Intended to receive first line immunotherapy (as monotherapy or in combination with chemotherapy). Patients who have had previous exposure to immunotherapy in the neoadjuvant or adjuvant setting are allowed to enroll as long as 12 months have elapsed since the prior exposure.\n\n  * Patients in surveillance on Cohort 1 are eligible to roll over to Cohort 2 at the time of recurrence as long as they have had histologic confirmation of recurrence and have been off immunotherapy for 12 months or greater and meet all other inclusion\u002Fexclusion criteria.\n* Tumors that lack activating EGFR mutations (e.g., exon 19 deletion or exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S768I mutation) and ALK fusions. Also, per NCCN Guideline recommended testing, tumors must also lack ROS1, BRAF, NTRK 1\u002F2\u002F3, METex14 skipping mutations, and RET for which there is available front-line targeted therapy. Only those patients with KRAS G12C mutations and ERBB2 (HER2) mutations with no contraindications to immunotherapy (PD-L1 1) for which there are no approved front-line targeted therapies and for whom immunotherapy would be the preferred front-line therapy are eligible.\n* Patients may be enrolled with local molecular testing and those results will be provided.\n\n  * Patients may be enrolled with local molecular testing and those results will be provided.\n* 18 years and older\n* Willing and able to provide informed consent\n* Willing to have additional blood samples collected during routine surveillance visits\n* Must submit tumor sample representative of current disease\n\nExclusion Criteria (both Cohorts):\n\n* Patients without a known or suspected NSCLC diagnosis, or other disease processes such as sarcoidosis, lymphoma, or metastatic cancer from other sites.\n* Not willing to have additional blood samples collected\n* Patients with a secondary malignancy must have been both diagnosed \\> 2 years from the lung cancer of interest and have completed all therapy for that malignancy (including extended adjuvant therapy) \\> 2 years prior to diagnosis of the lung cancer of interest with the exception of the following:\n* Patients with superficial basal cell carcinoma of low-risk histology per NCCN Guidelines (Low-risk histologic subtypes include nodular, superficial, and other non-aggressive growth patterns such as keratotic, infundibulocystic, and fibroepithelioma of Pinkus) and low-risk for recurrence per NCCN Guidelines (location on trunk or extremities, size \\\u003C 2 cm, primary (not recurrent), with well-defined borders) can be included even if they are diagnosed \\\u003C 2 years from the lung cancer of interest.\n* Patients with superficial squamous cell carcinoma of low-risk pathology per NCCN Guidelines (verrucous, keratoacanthomatous) and low-risk for recurrence per NCCN Guidelines (located on trunk or extremities; 2 cm in size; primary lesion (vs. recurrent); well to moderately differentiated; \\\u003C 2 mm thick and no invasion beyond subcutaneous fat; negative for perineural invasion; and negative for lymphatic or vascular involvement) can be included even if they are diagnosed \\\u003C 2 years from the lung cancer of interest.",{"count":190,"type":21},1200,"GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.",[193],"Non-Small Cell Lung Cancer",[90,91,92,93,94,193,195,65,96],"NSCLC","2026-02-03",{"date":198,"type":35},"2026-02-05",{"date":200,"type":35},"2022-06-22",{"date":202,"type":21},"2029-06",{"name":41,"class":42},58,{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":227},"100457252","tempus-crc-surveillance-study-a-ctdna-biomarker-profiling-study-of-patients-with-crc-using-ngs-assays-100457252","NCT05234177","Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays","Tempus CRC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Colorectal Cancer (CRC) Using Comprehensive Next-Generation Sequencing (NGS)Assays","Inclusion Criteria:\n\n* Known or suspected colorectal adenocarcinoma (Stage I to IVA disease)\n* Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent.\n* 18 years old or older\n* Willing and able to provide informed consent\n* Willing to have additional blood samples collected during routine surveillance visits\n\nExclusion Criteria:\n\n* Not willing to have additional blood samples collected\n* Pathology that is not consistent with colorectal adenocarcinoma",{"count":213,"type":21},300,"The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.",[216],"Colorectal Cancer",[90,91,92,93,94,218,216,65,96],"CRC","2025-05-05",{"date":221,"type":35},"2025-05-06",{"date":223,"type":35},"2022-06-21",{"date":225,"type":21},"2029-02",{"name":41,"class":42},20,""]